AbbVie recently presented 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD) portfolio at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee, USA.
Data presented will include newly unveiled AFFIRM results showing efficacy for Skyrizi (risankizumab-rzaa) in advanced therapy-naïve Crohn’s disease (CD) patients, open-label extension analyses demonstrating long-term outcomes with Skyrizi in difficult-to-treat IBD and growing real-world evidence supporting Rinvoq (upadacitinib) in advanced CD.
